Last reviewed · How we verify

NCT04979117: SMI

Superb Microvascular Imaging Ultrasonography of Plantar Fasciitis

Completed Last updated 28 December 2022
What this trial tests

trial testing Superb Microvascular Imaging (SMI) (Toshiba) in Diagnose Disease in 60 participants. Completed in 27 December 2022.

Timeline
28 May 2021
Primary endpoint
27 December 2022
27 December 2022

Quick facts

Lead sponsorNigde Omer Halisdemir University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment60
Start date28 May 2021
Primary completion27 December 2022
Estimated completion27 December 2022
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Nigde Omer Halisdemir University

Who can join

Adults 18 to 45, any sex, with Diagnose Disease or Plantar Fasciitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective study will be conducted to evaluate the diagnostic performance of SMI, gray scale US, color Doppler US and Power Doppler US.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Superb Microvascular Imaging (SMI) (Toshiba)

Trials testing the same drug.

Other recruiting trials for Diagnose Disease

Currently open trials in the same condition.

Other Nigde Omer Halisdemir University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04979117.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing